Stem Holdings Past Earnings Performance
Past criteria checks 0/6
Stem Holdings has been growing earnings at an average annual rate of 12.1%, while the Pharmaceuticals industry saw earnings growing at 67.6% annually. Revenues have been growing at an average rate of 24.6% per year.
Key information
12.1%
Earnings growth rate
64.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 24.6% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Stem Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -5 | 4 | 0 |
| 30 Jun 23 | 16 | -19 | 10 | 0 |
| 31 Mar 23 | 16 | -16 | 11 | 0 |
| 31 Dec 22 | 16 | -17 | 12 | 0 |
| 30 Sep 22 | 0 | -3 | 7 | 0 |
| 30 Jun 22 | 17 | -8 | 16 | 0 |
| 31 Mar 22 | 18 | -6 | 18 | 0 |
| 31 Dec 21 | 20 | -10 | 18 | 0 |
| 30 Sep 21 | 21 | -10 | 18 | 0 |
| 30 Jun 21 | 21 | -10 | 17 | 0 |
| 31 Mar 21 | 21 | -14 | 15 | 0 |
| 31 Dec 20 | 18 | -11 | 15 | 0 |
| 30 Sep 20 | 14 | -11 | 13 | 0 |
| 30 Jun 20 | 10 | -27 | 20 | 0 |
| 31 Mar 20 | 5 | -29 | 21 | 0 |
| 31 Dec 19 | 3 | -28 | 19 | 0 |
| 30 Sep 19 | 2 | -29 | 19 | 0 |
| 30 Jun 19 | 1 | -13 | 11 | 0 |
| 31 Mar 19 | 1 | -14 | 13 | 0 |
| 31 Dec 18 | 1 | -12 | 11 | 0 |
| 30 Sep 18 | 1 | -9 | 9 | 0 |
| 30 Jun 18 | 1 | -7 | 8 | 0 |
| 31 Mar 18 | 1 | -3 | 4 | 0 |
| 31 Dec 17 | 1 | -3 | 3 | 0 |
| 30 Sep 17 | 0 | -3 | 3 | 0 |
Quality Earnings: STEM is currently unprofitable.
Growing Profit Margin: STEM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STEM is unprofitable, but has reduced losses over the past 5 years at a rate of 12.1% per year.
Accelerating Growth: Unable to compare STEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STEM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Return on Equity
High ROE: STEM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.